Entity

Time filter

Source Type


Trademark
Bioinvent International Ab | Date: 2002-11-05

proteins for scientific and research use; chemical preparations for use in protein analysis; chemicals and chemical preparations for use in the manufacture of pharmaceuticals; proteins for immunoassay for detection of cancer, autoimmune disease, infection, cardiovascular disease, liver dysfunction, kidney dysfunction, inflammatory disease and for toxicological studies for scientific use; proteins for biotechnological purposes, namely, chromatography; [ binding proteins and immunoassay reagents contained in boxes, trays or other receptacles, sold together as a unit, for scientific use ]. diagnostic proteins for clinical or medical laboratory analysis; proteins for therapeutic use for treating cancer, autoimmune disease, infection, cardiovascular disease, liver dysfunction, kidney dysfunction, toxicological conditions and inflammatory disease; biopharmaceuticals for use in cancer, autoimmune disease, infection, cardiovascular disease, liver dysfunction, kidney dysfunction, inflammatory disease and toxicological conditions;[ laboratory testing kits for clinical or medical purposes comprising a box, tray or other receptacle holding vials containing binding proteins and immunoassays reagents, sold together as a unit ]. [ laboratory testing kits for research purposes comprising a box, tray or other receptacle holding vials containing binding proteins and immunoassay reagents, sold together as a unit ]. Contract manufacturing of antibodies for third parties. Scientific research and pharmaceutical drug development services, for others.


Trademark
Bioinvent International Ab | Date: 2003-10-14

[ Chemicals for scientific, laboratory or medical research; chemicals for use in the manufacture of pharmaceuticals; libraries and collections of aforementioned chemicals for scientific, laboratory or medical research; biochemicals, namely, antibodies for scientific, laboratory or medical research; libraries and collections of antibodies for scientific, laboratory or medical research ]. [ Chemicals for clinical, therapeutic and diagnostic medical purposes, namely, peptides, proteins, nucleic acids, genes and oligonucleotides; antibodies and libraries of antibodies for clinical, therapeutic and diagnostic medical purposes ]. Medical and scientific laboratory services, namely, providing access to a library of antibodies; selecting and extracting antibodies from a library of antibodies.


Trademark
Bioinvent International Ab | Date: 2001-01-29

Chemicals for scientific, laboratory or medical research; chemicals for use in the manufacture of pharmaceuticals; libraries and collections of aforementioned chemicals for scientific, laboratory or medical research; biochemicals, namely, antibodies for scientific, laboratory or medical research; libraries and collections of antibodies for scientific, laboratory or medical research. Chemicals for clinical, therapeutic and diagnostic medical purposes, namely, peptides, proteins, nucleic acids, genes and oligonucleotides; antibodies and libraries of antibodies for clinical, therapeutic and diagnostic medical purposes.


Grant
Agency: Cordis | Branch: H2020 | Program: SME-1 | Phase: PHC-12-2014-1 | Award Amount: 71.43K | Year: 2015

The overall objective of the proposed project is the clinical validation of a novel biomarker for B-cell malignancies. The presently most widely used anti-CD20 antibody treatment rituximab has considerably improved treatment options for patients with B-cell malignancies. However, effectiveness is limited by resistance to rituximab and reduced response on repeated treatments. Data indicates that tumor expression of CD32b is directly involved in the development of resistance to rituximab. CD32b has the potential to be used as predictive biomarker for critical clinical decisions for rituximab and related treatments, and will impact payers and patients. In addition, our company is developing a novel treatment BI-1206 that specifically targets CD32b and significantly improves antitumor effects of rituximab alone. As such, the CD32b biomarker assay has the additional potential to become a companion diagnostic for BI-1206 and other future B-cell malignancy treatments. Our company and the affiliated research team have developed a flow cytometry assay for the detection of the CD32b receptor on tumor cells. The assay has been partially validated in a clinically relevant setting to demonstrate CD32b as a predicative biomarker of therapy response. To achieve market uptake of our technology, we aim to conduct a number of studies together with selected clinical partners in Europe. The objectives of the feasibility study are to find and contact researchers/clinicians for conducting retrospective and/or prospective studies, as well as to refine the business model for the commercialization of the biomarker assay. The intended users of our product are clinicians and therapy developers that focus on B-cell malignancies. By clinically validating a biomarker assay for B-cell malignancies and especially CLL, our company addresses an unmet European and global need for improved treatments for CLL, and B-cell malignancies in general.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2007-1.4-1 | Award Amount: 7.86M | Year: 2008

Cancer is the second leading cause of death in European countries, and one of the most imminent health problems in the developed world. Innovative, so-called targeted therapies are urgently needed that aim specifically at cancer cells or to cells of the stroma that support tumor growth. The ultimate goal of a targeted therapy is to increase anti-tumor efficacy with lowest possible side effects. Rapid and efficient translation of basic scientific advances into reagents, and targeted molecular leads for preclinical and clinical research and development based on scientific rationales and state-of-the-art technologies, optimally requires an interdisciplinary, collaborative, team-oriented approach. EUCAAD represents a virtual research institute in Europe and consists of 9 research participants including 4 SMEs devoted to the discovery and evaluation of new antibodies for therapy of human cancers. The consortium consists of researchers from SMEs and scientific and clinical centres that have gained international acclaim in this area of research, many of who have worked together in previous EU funded applications e.g. ANGIOSTOP, EUCAPS, ESTDAB and ENACT. Within the consortium there is unique expertise regarding target discovery, target validation, antibody production and initiation of clinical trials. As part of its efforts to translate laboratory research into viable cancer therapies the individual partners has accumulated an extensive portfolio of intellectual property providing a competitive edge to this application. The focus of the grant is the development and evaluation of antibodies against new target structures on tumour cells and blood vessels supplying tumours which are responsible for tumour angiogenesis, progression and metastasis. Collectively, the activities of this consortium can improve the cancer treatment standards in Europe and provide economic benefit to European biotechnology and pharmaceutical research by providing novel immunopharmaceuticals.

Discover hidden collaborations